Updated FLUBLOK label expands influenza vaccine options for pregnant women

In a recent interview, Ruth M Carrico, PhD, DNP, APRN, a family nurse practitioner and infectious diseases expert, discussed the updated FLUBLOK vaccine label to include safety in pregnant women.

Carrico expressed her excitement about the update, particularly in light of her experiences treating pregnant women who have developed influenza. FLUBLOK, a recombinant influenza vaccine, has now been included in Centers for Disease Control and Prevention and American College of Obstetrics and Gynecologists recommendations for pregnant and expectant patients. This inclusion adds to the range of available vaccines, allowing health care providers more flexibility when recommending influenza vaccinations for this vulnerable population.

There are risks associated with influenza infection during pregnancy that providers must be aware of. Pregnant women face heightened vulnerabilities caused by physiological changes, and the consequences of influenza infection can be severe. The infection can lead to respiratory illnesses, cardiovascular issues, and, in the worst cases, pneumonia, hospitalization, or even death. The fetus may also be at risk because of these complications.

Carrico also discussed results of the study results evaluating FLUBLOK in pregnant women, highlighting that the study showed no increased risk of adverse events, such as pregnancy complications, birth outcomes, or neonatal issues, when comparing FLUBLOK to standard influenza vaccines. This is reassuring for health care providers, as it indicates that no vaccine should be withheld when influenza prevention is indicated in this population.

Carrico concluded by noting that the availability of FLUBLOK simplifies the vaccination process, particularly for patients who may have concerns, such as avoiding egg-based vaccines. Having more options allows for better patient education, encourages vaccination, and ultimately helps avoid preventable complications, particularly respiratory illnesses, in pregnant women. The broader toolkit empowers health care professionals to make stronger recommendations and ensure better patient outcomes.